An interventional study of Airway pressure release ventilation and low tidal volume in Right Heart Failure, Mechanical Ventilation and Acute Respiratory Distress Syndrome, sponsored by XiaoJing Zou,MD. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-18.
Sponsored by XiaoJing Zou,MD · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 377 studies in Heart Failure with a site in China — 162 open to participants now, 182 under way, 18 of them phase 3. Heart Failure · China.
Among the 377 studies in Heart Failure with a site in China, this one is the 180th largest by enrollment of the 247 interventional ones that give a count, is one of 43 that started in 2023, is one of 115 with no phase, and was the 207th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →162 of the 377 studies in Heart Failure with a site in China are open now. Recruiting first, the newest first:
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 65+
Jiangsu Taizhou People's Hospital · Sites in China
Ages 65+ · Healthy volunteers
AstraZeneca · Sites in China, United States, Argentina and 29 more countries
Ages 18+
Pulnovo Medical, Inc. · Sites in China, United States
Ages 18–85
Tasly Pharmaceutical Group Co., Ltd · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
377 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 44 · Phase 3 49 · Phase 4 30
First in 1983; this study’s year is marked. 43 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 130 across the 247 interventional studies, 554 across the 130 observational. Of the 117 that completed or were terminated, 33 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
109 of 377 have an industry lead sponsor. The 10 most frequent:
XiaoJing Zou,MD is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
XiaoJing Zou,MD has 1 study filed under Heart Failure — fewer than ten, so there is no comparison to draw.
47 of the studies in Heart Failure with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06307652Phase 3AstraZenecaStudy to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | 2027-04-16 |
| NCT07496372Phase 3HELP Therapeutics Co., Ltd.A Pivotal Clinical Trial of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advanced Heart Failure(NYHA III-IV) | 2027-06-30 |
| NCT06736574Phase 3CytokineticsStudy With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | 2027-09 |
| NCT06024746Phase 3Colorado Prevention CenterA Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) | 2027-11 |
| NCT06927440Shanghai Jiao Tong University School of MedicineNational Multicenter Registry for Pediatric End-Stage Heart Failure in China | 2026-11-30 |
Add all 47 to your calendar (.ics) → With an account.
Among the 377 studies in Heart Failure with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Acute Respiratory Distress Syndrome (ARDS) is often complicated by Right Ventricular Dysfunction (RVD), and the incidence can be as high as 64%. The mechanism includes pulmonary vascular dysfunction and right heart systolic dysfunction. Pulmonary vascular dysfunction includes acute vascular inflammation, pulmonary vascular edema, thrombosis and pulmonary vascular remodeling. Alveolar collapse and over distension can also lead to increased pulmonary vascular resistance, Preventing the development of acute cor pulmonale in patients with acute respiratory distress. ARDS patients with RVD have a worse prognosis and a significantly increased risk of death, which is an independent risk factor for death in ARDS patients. Therefore, implementing a right heart-protective mechanical ventilation strategy may reduce the incidence of RVD.
APRV is an inverse mechanical ventilation mode with transient pressure release under continuous positive airway pressure, which can effectively improve oxygenation and reduce ventilator-associated lung injury. However, its effect on right ventricular function is still controversial. Low tidal volume (LTV) is a mechanical ventilation strategy widely used in ARDS patients. Meta-analysis results showed that compared with LTV, APRV improved oxygenation more significantly, reduced the time of mechanical ventilation, and even had a tendency to improve the mortality of ARDS patients However, randomized controlled studies have shown that compared with LTV, APRV improves oxygenation more significantly and also increases the mean airway pressure. Therefore, some scholars speculate that APRV may increase the intrathoracic pressure, pulmonary circulatory resistance, and the risk of right heart dysfunction but this speculation is not supported by clinical research evidence. In addition, APRV may improve right ventricular function by correcting hypoxia and hypercapnia, promoting lung recruitment and reducing pulmonary circulation resistance. Therefore, it is very important to clarify this effect for whether APRV can be safely used and popularized in clinic.we aim to conduct a single-center randomized controlled study to further compare the effects of APRV and LTV on right ventricular function in patients with ARDS, pulmonary circulatory resistance (PVR) right ventricular-pulmonary artery coupling (RV-PA coupling), and pulmonary vascular resistance (PVR).
Acute Respiratory DistressSyndrome (ARDS) is often complicated by Right Ventricular Dysfunction (RVD), and the incidence can be as high as 64%. The mechanism includes pulmonary vascular dysfunction and right heart systolic dysfunction. Pulmonary vascular dysfunction includes acute vascular inflammation, pulmonary vascular edema, thrombosis and pulmonary vascular remodeling. Alveolar collapse and alveolar overdistension can also lead to increased pulmonary vascular resistance, Preventing the development of acute cor pulmonale in patients with acute respiratory distress. ARDS patients with RVD have a worse prognosis and a significantly increased risk of death, which is an independent risk factor for death in ARDS patients [2-4]. Therefore, implementing a right heart-protective mechanical ventilation strategy may reduce the incidence of RVD.
Mechanical ventilation is the main treatment for moderate to severe ARDS. Mechanical ventilation promotes lung recruitment and reduces mechanical compression of pulmonary vessels between alveoli and alveolar walls. In addition, mechanical ventilation corrected hypoxemia and hypercapnia, thereby reducing reactive pulmonary vasoconstriction. All of the above can reduce pulmonary circulation resistance and right ventricular afterload, thereby improving right ventricular function in patients with ARDS. However, if hyperventilation occurs, it will increase the mechanical compression of pulmonary vessels on the alveolar wall, increase the intrathoracic pressure, and increase the afterload of the right heart, which will adversely affect the function of the right heart. There are a variety of ventilation strategies for patients with ARDS in clinical practice, but which mechanical ventilation has the protective function of right heart or has little effect on right heart function, so far there is a lack of relevant research reports.
Airway pressure release ventilation (APRV) is an inverse mechanical ventilation mode with transient pressure release under continuous positive airway pressure, which can effectively improve oxygenation and reduce ventilator-associated lung injury. However, its effect on right ventricular function is still controversial, so its clinical application is not popular, and it is only used as one of the salvage treatments for ARDS patients. Low tidal volume (LTV) is a mechanical ventilation strategy widely used in ARDS patients, but it does not further reduce mortality in patients with moderate to severe ARDS. Meta-analysis results showed that compared with LTV, APRV improved oxygenation more significantly, reduced the time of mechanical ventilation, and even had a tendency to improve the mortality of ARDS patients [7]. However, randomized controlled studies have shown that compared with LTV, APRV improves oxygenation more significantly and also increases the mean airway pressure [8]. Therefore, some scholars speculate that APRV may increase the intrathoracic pressure, pulmonary circulatory resistance, and the risk of right heart dysfunction , but this speculation is not supported by clinical research evidence. In addition, the results of animal experiments suggest that APRV improves oxygenation, promotes lung recruitment, and improves the heterogeneity of lung lesions in ARDS, without causing lung hyperventilation, suggesting that APRV may not increase pulmonary circulatory resistance. In addition, APRV may improve right ventricular function by correcting hypoxia and hypercapnia, promoting lung recruitment and reducing pulmonary circulation resistance. Therefore, the impact of APRV on right ventricular function is still unclear, and it is very important to clarify this effect for whether APRV can be safely used and popularized in clinic. Therefore, our research group conducted a prospective observational study, "The effect of APRV on right ventricular function evaluated by Transthoracic Echocardiography, [2022] Lun Lun Zi (0075)". The study results suggested that APRV improved lung perfusion in ARDS patients while effectively improving oxygenation and promoting lung recruitment. The incidence of RVD was not increased, and there was no hemodynamic deterioration in ARDS patients. APRV is safe and effective for patients with ARDS. However, the results of a single-arm prospective observational study with a small sample size cannot provide strong evidence for clinical practice. In the previous studies, all the right ventricular function was assessed by transthoracic echocardiography. Due to the limitation of the sound window of transthoracic echocardiography, the right ventricular function of some ARDS patients could not be evaluated. Therefore, this study intends to use transesophageal echocardiography or transthoracic echocardiography to fully evaluate the right ventricular function of all enrolled patients as much as possible, and to conduct a single-center randomized controlled study to further compare the effects of APRV and LTV on right ventricular function in patients with ARDS, pulmonary circulatory resistance (PVR), right ventricular-pulmonary artery coupling (RV-PA coupling), and pulmonary vascular resistance (PVR).Whether there are different effects on hemodynamics and mortality. It is hoped that the results of this study will provide more evidence support for the clinical application of APRV and benefit more ARDS patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In APRV group, ventilator parameters were set according to the study protocol, P high: Tidal volume (VT) was set at 6ml/kg of ideal body weight, and plateau pressure (Pplat) was measured. Initial Phigh was set at Pplat, usually 20-32 cmH2O. The APRV end-expiratory flow rate was set at 75% of the peak expiratory flow rate.
Procedure: Airway pressure release ventilation
The ARDSnet method was used for LTV group mechanical ventilation, and the tidal volume was set according to 4-8ml/kg, so that the Pplat was \<30cmH2O
Procedure: low tidal volume
ventilator parameters were set according to the study protocol, P high: Tidal volume (VT) was set at 6ml/kg of ideal body weight, and plateau pressure (Pplat) was measured. Initial Phigh was set at Pplat, usually 20-32 cmH2O. The APRV end-expiratory flow rate was set at 75% of the peak expiratory flow rate.
The ARDSnet method was used for LTV mechanical ventilation, and the tidal volume was set according to 4-8ml/kg, so that the Pplat was \<30cmH2O
Incidence of right heart dysfunction in ARDS patients with APRV or LTV mechanical ventilation for 24h
Incidence of right heart dysfunction in ARDS patients with APRV or LTV mechanical ventilation for 24h.Abnormal findings on any of the following ultrasound measures can be considered as right ventricular dysfunction, including: tricuspid annular plane systolic excursion (TAPSE) \<17 mm, tricuspid annular plane systolic velocity (S') \<9.5 cm/s, right ventricular fractional area change (FAC) \<35%, ratio of right ventricular end-diastolic area to left ventricular end-diastolic area (RVEDA/LVEDA) \>0.6, or right ventricular to left ventricular end-diastolic diameter ratio (RV/LV ratio) \>1.
Time frame: at the time of 24 hours after inclusion
Incidence of right heart dysfunction in ARDS patients with APRV or LTV mechanical ventilation for 48h
Incidence of right heart dysfunction in ARDS patients with APRV or LTV mechanical ventilation for 24h.Abnormal findings on any of the following ultrasound measures can be considered as right ventricular dysfunction, including: right ventricular end-diastolic diameter/left ventricular end-diastolic diameter(RVEDD/LVEDD)\>1.0, right ventricular fractional area change(FAC)\<35%,tricuspid annular plane systolic excursion(TAPSE)\<17mm,Systolic S'velocity of tricuspid annulus \<9.5 cm/s by TDI
Time frame: at the time of 48 hours after inclusion
Incidence of right heart dysfunction in ARDS patients with APRV or LTV mechanical ventilation for 72h
Incidence of right heart dysfunction in ARDS patients with APRV or LTV mechanical ventilation for 24h.Abnormal findings on any of the following ultrasound measures can be considered as right ventricular dysfunction, including: right ventricular end-diastolic diameter/left ventricular end-diastolic diameter(RVEDD/LVEDD)\>1.0, right ventricular fractional area change(FAC)\<35%,tricuspid annular plane systolic excursion(TAPSE)\<17mm,Systolic S'velocity of tricuspid annulus \<9.5 cm/s by TDI
Time frame: at the time of 72 hours after inclusion
Values of tricuspid annular plane systolic excursion at 24th hour
Tricuspid annular plane systolic excursion(TAPSE) was measured by echocardiography in the apical four-chamber view, using M mode measurements, with the sampling line aligned to the tricuspid annulus.
Time frame: at the time of 24 hours after inclusion
Values of tricuspid annular plane systolic excursion at 48th hour
Tricuspid annular plane systolic excursion(TAPSE) was measured by echocardiography in the apical four-chamber view, using M mode measurements, with the sampling line aligned to the tricuspid annulus.
Time frame: at the time of 48 hours after inclusion
Values of tricuspid annular plane systolic excursion at 72th hour
Tricuspid annular plane systolic excursion(TAPSE) was measured by echocardiography in the apical four-chamber view, using M mode measurements, with the sampling line aligned to the tricuspid annulus.
Time frame: at the time of 72 hours after inclusion
Values of right ventricular end-diastolic diameter/left ventricular end-diastolic diameter(RVEDD/LVEDD) at 24th hour
The maximum transverse diameter of the right/left ventricular inflow tract near the basal 1/3 was measured in the apical four-chamber view
Time frame: at the time of 24 hours after inclusion
Values of right ventricular end-diastolic diameter/left ventricular end-diastolic diameter(RVEDD/LVEDD) at 48th hour
The maximum transverse diameter of the right/left ventricular inflow tract near the basal 1/3 was measured in the apical four-chamber view
Time frame: at the time of 48 hours after inclusion
Values of right ventricular end-diastolic diameter/left ventricular end-diastolic diameter(RVEDD/LVEDD) at 72th hour
The maximum transverse diameter of the right/left ventricular inflow tract near the basal 1/3 was measured in the apical four-chamber view
Time frame: at the time of 72 hours after inclusion
Values of right ventricular fractional area change(RVFAC) at 24th hour
RVFAC = (end-diastolic area - end-systolic area)/end-diastolic area ×100%.The right ventricle is shown in the apical four-chamber cardiac view.
Time frame: at the time of 24 hours after inclusion
Values of right ventricular fractional area change(RVFAC) at 48th hour
RVFAC = (end-diastolic area - end-systolic area)/end-diastolic area ×100%.The right ventricle is shown in the apical four-chamber cardiac view.
Time frame: at the time of 48 hours after inclusion
Values of right ventricular fractional area change(RVFAC) at 72th hour
RVFAC = (end-diastolic area - end-systolic area)/end-diastolic area ×100%.The right ventricle is shown in the apical four-chamber cardiac view.
Time frame: at the time of 72 hours after inclusion
Values of Systolic S'velocity of tricuspid annulus by at 24th, 48th and 72th hour
Tissue Doppler sampling volume is placed in the middle of the right ventricular tricuspid annulus or basal segment of the right ventricular free wall to measure systolic velocity S'.
Time frame: at the time of 24 hours (h), 48h and 72h after inclusion
Values of hemodynamic measures at 24th, 48th and 72th hour
hemodynamic measures including: heart rate, mean arterial pressure,central venous pressure,Dose of vasoactive agents accumulated over 24 hours,cumulative fluid balance over 24 hours.
Time frame: at the time of 24 hours (h), 48h and 72h after inclusion
Values of respiratory mechanics parameters at 24th, 48th and 72th hour
Respiratory mechanics parameters including Peak pressure, Plateau pressure,Driving pressure,Respiratory system compliance and Airway resistance are measured by using routine procedures
Time frame: at the time of 24 hours (h), 48h and 72h after inclusion
28-day mortality
28-day mortality after study entry
Time frame: Day 28 after study entry
in hospital mortality
in hospital mortality after study entry
Time frame: Maximum 90-day in-hospital mortality
28 days of ventilator free days
28 days of ventilator free days after study entry
Time frame: Day 28 after study entry
Values of arterial partial pressure of oxygen/fraction of inspired oxygen at 24th, 48th and 72th hour
arterial partial pressure of oxygen/fraction of inspired oxygen are measured at 24th, 48th and 72th hour after inclusion
Time frame: at the time of 24 hours (h), 48h and 72h after inclusion
Values of arterial partial pressure of carbon dioxide at 24th, 48th and 72th hour
arterial partial pressure of carbon dioxide are measured at 24th, 48th and 72th hour after inclusion
Time frame: at the time of 24 hours (h), 48h and 72h after inclusion
ventilation ratio at 24th, 48th and 72th hour
VR=\[minute ventilation ×PaCO2\]/\[predicted body weight ×100×37.5\]
Time frame: at the time of 24 hours (h), 48h and 72h after inclusion
Incidence prone position ventilation during hospitalization
Incidence of prone position ventilation during hospitalization after study entry
Time frame: Day 28 after study entry
ventilator settings at 24th, 48th and 72th hour
ventilator settings including minute ventilation, Fraction of inspired oxygen, tidal volume, positive end-expiratory pressure, respiratory rate, mean airway pressure
Time frame: at the time of 24 hours (h), 48h and 72h after inclusion
Velocity-time integral of left ventricular outflow tract at 24th, 48th and 72th hour
Velocity-time integral(Vti) of left ventricular outflow tract are measured at the apical five-chamber heart view. The sampling volume was placed in the left ventricular outflow tract, below the aortic valve, in pulsed Doppler mode with a window width of 2-4mm. The velocity time integral (VTI) image of aortic blood flow can be obtained by placing the sampling volume below the aortic valve orifice , adjusting the probe so that the direction of blood flow is as parallel as possible to the sampling line, and selecting the pulsed Doppler mode (PW)
Time frame: at the time of 24 hours (h), 48h and 72h after inclusion
Stroke volume at 24th, 48th and 72th hour
Stroke volume(SV)=15.VTI×π(D/2)\*(D/2), D=Left ventricular outflow tract diameter(LVOT diameter)
Time frame: at the time of 24 hours (h), 48h and 72h after inclusion
cardiac output at 24th, 48th and 72th hour
cardiac output(CO)=SV\*HR
Time frame: at the time of 24 hours (h), 48h and 72h after inclusion
Velocity-time integral of right ventricular outflow tract at 24th, 48th and 72th hour
Velocity-time integral(Vti) of right ventricular outflow tract are measured at the view of the right ventricular outflow tract. The sampling volume was placed in the right ventricular outflow tract, below the aortic valve, in pulsed Doppler mode with a window width of 2-4mm. The velocity time integral (VTI) image of aortic blood flow can be obtained by placing the sampling volume below the aortic valve orifice , adjusting the probe so that the direction of blood flow is as parallel as possible to the sampling line, and selecting the pulsed Doppler mode (PW)
Time frame: at the time of 24 hours (h), 48h and 72h after inclusion
Tricuspid annular diameter
Tricuspid annular diameters are measured at the apical four-chamber heart view
Time frame: at the time of 24 hours (h), 48h and 72h after inclusion
The velocity of tricuspid regurgitation
The velocity of tricuspid regurgitation are measured at the apical four-chamber heart view.The CW Doppler sampling line was placed at the tricuspid valve orifice.
Time frame: at the time of 24 hours (h), 48h and 72h after inclusion
Length of hospital stay
hospital stay after hospital entry
Time frame: Maximum 90-day hospital stay
Length of ICU stay
hospital stay after ICU entry
Time frame: Maximum 90-day ICU stay
Incidence of tracheotomy
Incidence of tracheotomy during hospitalization after study entry
Time frame: Day 28 after study entry
Ran from Jul 2023 to primary completion in Feb 2025, 18 months.
Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's 18 months is below that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
XiaoJing Zou,MD